Author:
Rincon-Torroella Jordina,Rakovec Maureen,Materi Josh,Raj Divyaansh,Vivas-Buitrago Tito,Ferres Abel,Reyes Serpa William,Redmond Kristin J.,Holdhoff Matthias,Bettegowda Chetan,González Sánchez José Juan
Abstract
Oligodendrogliomas are a subtype of adult diffuse glioma characterized by their better responsiveness to systemic chemotherapy than other high-grade glial tumors. The World Health Organization (WHO) 2021 brain tumor classification highlighted defining molecular markers, including 1p19q codeletion and IDH mutations which have become key in diagnosing and treating oligodendrogliomas. The management for patients with oligodendrogliomas includes observation or surgical resection potentially followed by radiation and chemotherapy with PCV (Procarbazine, Lomustine, and Vincristine) or Temozolomide. However, most of the available research about oligodendrogliomas includes a mix of histologically and molecularly diagnosed tumors. Even data driving our current management guidelines are based on post-hoc subgroup analyses of the 1p19q codeleted population in landmark prospective trials. Therefore, the optimal treatment paradigm for molecularly defined oligodendrogliomas is incompletely understood. Many questions remain open, such as the optimal timing of radiation and chemotherapy, the response to different chemotherapeutic agents, or what genetic factors influence responsiveness to these agents. Ultimately, oligodendrogliomas are still incurable and new therapies, such as targeting IDH mutations, are necessary. In this opinion piece, we present relevant literature in the field, discuss current challenges, and propose some studies that we think are necessary to answer these critical questions.
Funder
National Institute of Neurological Disorders and Stroke
Reference50 articles.
1. The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary;Louis;Neuro Oncol,2021
2. The 2007 WHO Classification of Tumours of the Central Nervous System;Louis;Acta Neuropathol,2007
3. Panel Review of Anaplastic Oligodendroglioma From European Organization For Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome;Kros;J Neuropathol Exp Neurol,2007
4. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors;Eckel-Passow;N Engl J Med,2015
5. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas;Brat;N Engl J Med,2015
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献